Bartter syndrome: Difference between revisions
TayyabaAli (talk | contribs) |
TayyabaAli (talk | contribs) No edit summary |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 16: | Line 16: | ||
'''For patient information click [[{{PAGENAME}} (patient information)|here]]''' | '''For patient information click [[{{PAGENAME}} (patient information)|here]]''' | ||
{{CMG}}{{AE}}{{TAM}} | {{CMG}}; {{AE}} {{TAM}} | ||
{{SK}} [[Bartter syndrome|Salt-wasting Renal Tubular Disorder]]; [[Bartter syndrome|Hyperprostaglandin E syndrome]]; [[Bartter syndrome|juxtaglomerular hyperplasia with secondary aldosteronism]]; [[Bartter syndrome|Barter disease]]; [[Bartter syndrome|Barter's disease]]; [[Bartter syndrome|Bartter disease]]; [[Bartter syndrome|Bartter's disease]] [[Hypokalemic Metabolic Alkalosis]] | {{SK}} [[Bartter syndrome|Salt-wasting Renal Tubular Disorder]]; [[Bartter syndrome|Hyperprostaglandin E syndrome]]; [[Bartter syndrome|juxtaglomerular hyperplasia with secondary aldosteronism]]; [[Bartter syndrome|Barter disease]]; [[Bartter syndrome|Barter's disease]]; [[Bartter syndrome|Bartter disease]]; [[Bartter syndrome|Bartter's disease]] [[Hypokalemic Metabolic Alkalosis]] | ||
| Line 34: | Line 34: | ||
==[[Bartter syndrome risk factors|Risk Factors]]== | ==[[Bartter syndrome risk factors|Risk Factors]]== | ||
==[[Bartter syndrome screening|Screening]]== | |||
==[[Bartter syndrome natural history, complications and prognosis|Natural History, Complications and Prognosis]]== | ==[[Bartter syndrome natural history, complications and prognosis|Natural History, Complications and Prognosis]]== | ||
| Line 41: | Line 42: | ||
==Treatment== | ==Treatment== | ||
[[Bartter syndrome medical therapy|Medical Therapy]] | [[Bartter syndrome surgery|Surgery]] | [[Bartter syndrome future or investigational therapies|Future or Investigational Therapies]] | [[Bartter syndrome medical therapy|Medical Therapy]] | [[Bartter syndrome surgery|Surgery]] | [[Bartter syndrome future or investigational therapies|Future or Investigational Therapies]] | [[Primary Prevention]] | [[Secondary Prevention]] | ||
==Case Studies== | ==Case Studies== | ||
Latest revision as of 14:46, 7 August 2020
| Bartter syndrome | |
| ICD-10 | E26.8 |
|---|---|
| ICD-9 | 255.13 |
| OMIM | 601678 241200 607364 602522 |
| DiseasesDB | 1254 |
| MeSH | D001477 |
|
Bartter syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Bartter syndrome On the Web |
|
American Roentgen Ray Society Images of Bartter syndrome |
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Tayyaba Ali, M.D.[2]
Synonyms and keywords: Salt-wasting Renal Tubular Disorder; Hyperprostaglandin E syndrome; juxtaglomerular hyperplasia with secondary aldosteronism; Barter disease; Barter's disease; Bartter disease; Bartter's disease Hypokalemic Metabolic Alkalosis
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Bartter syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Future or Investigational Therapies | Primary Prevention | Secondary Prevention